Harpoon Therapeutics Inc (NASDAQ:HARP) Director Mark Chin sold 47,752 shares of Harpoon Therapeutics stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $19.15, for a total value of $914,450.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Mark Chin also recently made the following trade(s):
- On Monday, December 9th, Mark Chin sold 103,754 shares of Harpoon Therapeutics stock. The stock was sold at an average price of $18.16, for a total value of $1,884,172.64.
Harpoon Therapeutics stock opened at $16.65 on Wednesday. The firm has a market capitalization of $439.09 million and a PE ratio of -0.65. Harpoon Therapeutics Inc has a 52 week low of $9.07 and a 52 week high of $21.26. The firm’s 50-day simple moving average is $15.07 and its 200 day simple moving average is $13.84. The company has a quick ratio of 7.37, a current ratio of 7.37 and a debt-to-equity ratio of 0.13.
Several hedge funds and other institutional investors have recently made changes to their positions in HARP. BlackRock Inc. lifted its holdings in shares of Harpoon Therapeutics by 216.8% in the second quarter. BlackRock Inc. now owns 294,047 shares of the company’s stock valued at $3,824,000 after purchasing an additional 201,237 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Harpoon Therapeutics by 183.3% during the 2nd quarter. Vanguard Group Inc. now owns 234,377 shares of the company’s stock worth $3,047,000 after purchasing an additional 151,644 shares in the last quarter. State Street Corp increased its stake in shares of Harpoon Therapeutics by 28.9% during the 3rd quarter. State Street Corp now owns 107,227 shares of the company’s stock worth $1,465,000 after purchasing an additional 24,064 shares in the last quarter. EcoR1 Capital LLC increased its stake in shares of Harpoon Therapeutics by 0.9% during the 2nd quarter. EcoR1 Capital LLC now owns 1,348,423 shares of the company’s stock worth $17,529,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Wells Fargo & Company MN acquired a new position in shares of Harpoon Therapeutics during the 2nd quarter worth approximately $94,000. 58.15% of the stock is currently owned by institutional investors.
A number of research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Harpoon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. Roth Capital began coverage on Harpoon Therapeutics in a report on Wednesday, November 13th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Canaccord Genuity reissued a “buy” rating and issued a $26.00 target price on shares of Harpoon Therapeutics in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.83.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Read More: Options Trading
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.